查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971075

傳染性腸炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按給藥途徑、藥物類型、地區和競爭格局分類，2021-2031年

Infectious Enteritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables), By Drug Type (Antibiotics, Antivirals, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球傳染性腸胃炎治療市場預計將從 2025 年的 5.1221 億美元大幅成長至 2031 年的 7.9182 億美元，複合年成長率為 7.53%。

此市場領域涵蓋抗生素和抗病毒藥物等藥物療法，以及用於治療由病原微生物引起的腸道發炎的補液療法。推動成長的關鍵因素是全球腹瀉疾病發生率的上升，以及由於醫療基礎設施投資增加而帶來的基本藥物可近性提高。例如，世界衛生組織（世衛組織）報告稱，2024年全球霍亂病例將比前一年增加5%，凸顯了對有效治療性介入的持續需求，以及受影響全部區域持續的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 5.1221億美元
市場規模：2031年 7.9182億美元
複合年成長率：2026-2031年 7.53%
成長最快的細分市場 口服
最大的市場 北美洲

阻礙市場發展的主要障礙是腸道病原體對抗生素抗藥性的日益增強。多重抗藥性菌株的傳播降低了標準抗生素療法的療效，導致臨床結果複雜，需要更精細的治療通訊協定。這個問題迫使製藥企業投入巨資研發替代療法，從而設置了重大的監管和經濟壁壘，限制了市場准入和成長。

市場促進因素

全球食源性和水源性腸道感染疾病的增加是市場需求的主要促進因素。諾羅病毒、沙門氏菌和李斯特菌等病原體正透過複雜的供應鏈和不完美的衛生措施傳播。根據英國健康安全局 (UKHSA) 2024 年 4 月發布的《國家諾羅病毒和輪狀病毒報告》，諾羅病毒檢測報告數量比過去五年的平均水平高出 75%，凸顯了疫情的波動性以及建立健全的口服補液鹽和症狀管理藥物供應鏈的緊迫性。此外，美國疾病管制與預防中心 (CDC) 於 2024 年報告了一起與熟食肉品相關的單核細胞增生李斯特菌感染疾病的嚴重集體爆發，導致 57 人住院治療。這再次強調了強而有力的抗生素介入和醫院治療方法的重要性。

同時，對新型抗菌和抗病毒療法研發投入的增加正在改變競爭格局。隨著傳統抗生素對抗藥性細菌的療效下降，公部門和私部門都在集中資金研發下一代治療方法。例如，英國政府於2024年5月宣布撥款8,500萬英鎊，專門用於支持抗菌素抗藥性研究和新型感染疾病治療方法的開發。這項財政支持將使製藥公司能夠加快臨床試驗並克服監管障礙，從而確保持續供應先進治療方法，以應對不斷演變的病原體威脅。

市場挑戰

抗生素抗藥性的蔓延是感染性腸炎治療市場成長的一大障礙。隨著越來越多的腸道病原體對標準抗生素療法產生抗藥性，現有藥物療法的臨床價值下降，迫使製藥公司投入大量研發新化合物。這項轉型需要進行複雜且成本高昂的研發舉措，失敗風險也高，導致利潤率下降，並阻礙新進者。因此，開發替代療法所帶來的經濟負擔造成了限制性的經濟環境，阻礙了治療方案的商業性擴充性。

近期監測數據進一步凸顯了這個挑戰，凸顯了問題的嚴重性。 2024年，歐洲疾病預防控制中心報告稱，在報告國家中，65.7%的人源性曲狀桿菌桿菌分離株對Ciprofloxacin有抗藥性。如此高的抗藥性加速了一線治療藥物的過時，並大幅縮短了現有治療方法的壽命。因此，市場面臨著產品持續貶值的惡性循環，阻礙了長期收入成長，並使維持有效藥物穩定供應所需的策略規劃更加複雜。

市場趨勢

市場正經歷著向微生物組調節療法的顯著轉變，尤其是在艱難梭菌感染疾病的治療方面，這種感染即使在接受標準抗生素治療後也容易復發。與破壞腸道生態系統的傳統抗菌藥物不同，這些生物治療產品旨在恢復腸道菌群，防止病原體再次定植，並打破復發循環。 VOWST 的成功為這一趨勢提供了商業性支持，VOWST 是 FDA 批准的首個口服微生物組療法。 Seres Therapeutics 公司報告稱，該藥物在 2024 年 5 月的第一季淨銷售額達到 1,010 萬美元，表明胃腸病學家正在迅速接受這種藥物，以尋求標準療法的替代方案。

同時，快速照護現場分子診斷技術的引入正在變革臨床管理。針對特定症候群的檢測組合取代了傳統的培養方法，使醫護人員能夠從一份糞便檢體中檢測出多種病毒、細菌和寄生蟲病原體，從而顯著縮短診斷時間，並實現靶向性強、頻譜窄的治療。生物梅里埃公司2024年9月發布的報告清楚展現了這些診斷組合的商業性成功。報告指出，BIOFIRE非呼吸道檢測組合（包括胃腸道解決方案）的銷售額在上半年實現了19%的內部成長，從而支持了更精準的治療方法和更最佳化的患者隔離通訊協定。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球傳染性腸炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（口服、注射）
    • 依藥物類型（抗生素、抗病毒藥物、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美感染性腸炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲傳染性腸炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區感染性腸炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲感染性腸炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲傳染性腸炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球傳染性腸炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi AG
  • Medtronic Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23954

The Global Infectious Enteritis Treatment Market is projected to expand significantly, rising from USD 512.21 Million in 2025 to USD 791.82 Million by 2031, reflecting a compound annual growth rate of 7.53%. This market sector includes pharmacotherapies like antibiotics and antivirals, as well as rehydration regimens designed to manage intestinal inflammation induced by pathogenic microorganisms. Growth is primarily underpinned by the increasing global incidence of diarrheal diseases and enhanced investment in healthcare infrastructure, which broadens access to vital medicines. For instance, the World Health Organization reported a 5% increase in global cholera cases in 2024 compared to the previous year, highlighting a persistent necessity for effective therapeutic interventions and ensuring sustained demand across affected regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 512.21 Million
Market Size 2031USD 791.82 Million
CAGR 2026-20317.53%
Fastest Growing SegmentOral
Largest MarketNorth America

A major obstacle hindering market progression is the rising prevalence of antimicrobial resistance among enteric pathogens. The spread of multidrug-resistant bacterial strains diminishes the efficacy of standard antibiotic treatments, resulting in complicated clinical outcomes and the need for intricate treatment protocols. This issue compels pharmaceutical developers to bear substantial costs in the pursuit of alternative therapies, establishing significant regulatory and economic barriers that limit market accessibility and growth.

Market Driver

The rising global prevalence of foodborne and waterborne enteric infections serves as a primary driver for market demand, as pathogens like Norovirus, Salmonella, and Listeria spread through complex supply chains and hygiene lapses. According to the United Kingdom Health Security Agency's 'National Norovirus and Rotavirus Report' from April 2024, laboratory reports of norovirus were 75% higher than the five-year average, underscoring the volatility of outbreaks and the urgent need for robust supply chains for rehydration salts and symptom-management drugs. Additionally, the Centers for Disease Control and Prevention noted a severe Listeria monocytogenes outbreak linked to deli meats in 2024 that caused 57 hospitalizations, reinforcing the critical necessity for potent antibiotic interventions and hospital-grade therapies.

Simultaneously, increased investment in research and development for novel antimicrobial and antiviral therapies is transforming the competitive landscape. To address the waning effectiveness of traditional antibiotics against resistant strains, both public and private sectors are directing capital toward next-generation treatments. For example, the United Kingdom Government announced an £85 million commitment in May 2024 specifically to support research into antimicrobial resistance and the development of new infectious disease treatments. This financial support helps pharmaceutical companies expedite clinical trials and navigate regulatory hurdles, ensuring a continuous pipeline of advanced therapeutic options to tackle evolving pathogenic threats.

Market Challenge

The growing prevalence of antimicrobial resistance poses a significant hurdle to the growth of the infectious enteritis treatment market. As enteric pathogens increasingly survive standard antibiotic regimens, the clinical value of existing pharmacotherapies declines, compelling pharmaceutical developers to invest heavily in discovering novel compounds. This transition requires complex, expensive research initiatives with high risks of failure, which reduces profit margins and deters new market entrants. Consequently, the financial strain of developing alternative therapies creates a restrictive economic climate that hampers the commercial scalability of treatment portfolios.

This challenge is reinforced by recent surveillance data highlighting the severity of the problem. In 2024, the European Centre for Disease Prevention and Control reported that 65.7% of Campylobacter coli isolates in humans across reporting countries were resistant to ciprofloxacin. Such high resistance rates hasten the obsolescence of frontline treatments, effectively shortening the viable lifespan of current inventories. As a result, the market contends with a continuous cycle of product devaluation, which obstructs long-term revenue growth and complicates the strategic planning necessary to maintain a steady supply of effective medicines.

Market Trends

The market is experiencing a significant shift toward microbiome-modulating therapeutics, particularly for managing recurrent Clostridioides difficile infections that frequently succeed standard antibiotic treatments. Unlike traditional antimicrobials that disturb gut ecology, these live biotherapeutic products are engineered to restore the intestinal microbial community, preventing pathogen recolonization and halting the cycle of recurrence. This trend is commercially supported by the success of the first FDA-approved oral microbiome therapy, VOWST; Seres Therapeutics reported in May 2024 that net sales for the drug reached $10.1 million in the first quarter, indicating rapid adoption by gastroenterologists seeking alternatives to standard care.

Concurrently, clinical management is being transformed by the adoption of rapid point-of-care molecular diagnostics, which replace slower culture methods with syndromic panel testing. These advanced platforms allow healthcare providers to detect a wide range of viral, bacterial, and parasitic pathogens from a single stool sample, drastically reducing diagnosis time and enabling targeted, narrow-spectrum treatment. The commercial success of these panels is evident in bioMerieux's September 2024 report, which noted that sales of BIOFIRE non-respiratory panels, including gastrointestinal solutions, grew organically by 19% in the first half of the year, supporting a more precise therapeutic approach and optimized patient isolation protocols.

Key Market Players

  • Novartis AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi A.G.
  • Medtronic Plc.

Report Scope

In this report, the Global Infectious Enteritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Enteritis Treatment Market, By Route of Administration

  • Oral
  • Injectables

Infectious Enteritis Treatment Market, By Drug Type

  • Antibiotics
  • Antivirals
  • Others

Infectious Enteritis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Enteritis Treatment Market.

Available Customizations:

Global Infectious Enteritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Enteritis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Injectables)
    • 5.2.2. By Drug Type (Antibiotics, Antivirals, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Infectious Enteritis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Infectious Enteritis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Infectious Enteritis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Infectious Enteritis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Type

7. Europe Infectious Enteritis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Infectious Enteritis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Infectious Enteritis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Infectious Enteritis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Infectious Enteritis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Infectious Enteritis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Infectious Enteritis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Infectious Enteritis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Infectious Enteritis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Infectious Enteritis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Infectious Enteritis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Infectious Enteritis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Infectious Enteritis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Infectious Enteritis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Infectious Enteritis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Infectious Enteritis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Type

10. South America Infectious Enteritis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Infectious Enteritis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Infectious Enteritis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Infectious Enteritis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Infectious Enteritis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences Inc
  • 15.3. GlaxoSmithKline plc
  • 15.4. Janssen Global Services, LLC
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. BioCryst Pharmaceuticals, Inc.
  • 15.7. Merck & Co., Inc.
  • 15.8. Boehringer Ingelheim GmbH
  • 15.9. Sanofi A.G.
  • 15.10. Medtronic Plc.

16. Strategic Recommendations

17. About Us & Disclaimer